Published in Am J Cardiol on November 01, 1990
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation (2008) 1.36
Heart rate variability and clinical cardiology. Br Heart J (1994) 1.04
Obesity is associated with impaired cardiac autonomic modulation in children. Int J Pediatr Obes (2010) 1.02
Sleep-disordered breathing and cardiac autonomic modulation in children. Sleep Med (2010) 1.00
Suppressed circadian heart rate dynamics in temporal lobe epilepsy. J Neurol Neurosurg Psychiatry (2005) 0.96
Cardiac Per2 functions as novel link between fatty acid metabolism and myocardial inflammation during ischemia and reperfusion injury of the heart. PLoS One (2013) 0.92
Circadian periodicity of heart rate variability in hospitalized angor patients. Clin Auton Res (2005) 0.92
Circadian rhythms in anesthesia and critical care medicine: potential importance of circadian disruptions. Semin Cardiothorac Vasc Anesth (2014) 0.85
Analysis of heart rate variability as an index of noncardiac surgical stress. Heart Vessels (2008) 0.84
Cardiac autonomic control mechanisms in power-frequency magnetic fields: a multistudy analysis. Environ Health Perspect (2000) 0.82
Gender differences in the impact of daily sadness on 24-h heart rate variability. Psychophysiology (2015) 0.78
Diurnal variation in the performance of rapid response systems: the role of critical care services-a review article. J Intensive Care (2016) 0.78
Differential autonomic mechanisms underlying early morning and daytime transient myocardial ischaemia in patients with stable coronary artery disease. Br Heart J (1995) 0.75
Heart rate variability in familial Mediterranean fever patients. Eur J Rheumatol (2014) 0.75
Cardiopulmonary resuscitation skills of preregistration house officers. Br Med J (Clin Res Ed) (1985) 8.45
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ (1995) 6.28
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet (1999) 3.38
Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J (1994) 3.13
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Chlamydia pneumoniae and coronary heart disease. BMJ (1997) 2.73
Colour Doppler flow mapping. BMJ (1990) 2.69
Left atrial appendage: structure, function, and role in thromboembolism. Heart (1999) 2.52
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (1997) 2.50
Cost implications of the British Pacing and Electrophysiology Group's recommendations for pacing. BMJ (1992) 2.42
Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol (1991) 2.42
Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 2.31
Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart (2002) 2.23
The QT interval. Prog Cardiovasc Dis (2001) 2.22
Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol (1994) 2.21
Atrial arrhythmias. Lancet (1993) 2.13
The rhythm of the heart in active elderly subjects. Am Heart J (1980) 2.02
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf (2001) 2.02
Complete denervation of the heart in a child with congenital long QT and deafness. Am J Cardiol (1988) 2.00
Cardiac arrhythmia suppression trial and flecainide. Lancet (1989) 1.98
Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. Lancet (1989) 1.96
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
Components of heart rate variability--what they really mean and what we really measure. Am J Cardiol (1993) 1.91
Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol (1992) 1.74
Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation (1998) 1.74
Effect of intravenous propranolol on QT interval. A new method of assessment. Br Heart J (1980) 1.71
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect (1995) 1.69
Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet (1988) 1.65
Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol (2000) 1.65
Classification of atrial fibrillation. Pacing Clin Electrophysiol (1997) 1.63
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J (1989) 1.59
Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol (1991) 1.58
Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol (1992) 1.58
Percutaneous treatment of portal venous stenosis in children and adolescents with segmental hepatic transplants: long-term results. Radiology (2000) 1.56
Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation (1989) 1.53
Limitations of rate response of an activity-sensing rate-responsive pacemaker to different forms of activity. Pacing Clin Electrophysiol (1988) 1.51
The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J (1984) 1.49
Catheter ablation for successful management of left posterior fascicular tachycardia: an approach guided by recording of fascicular potentials. Heart (1996) 1.47
Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants. Circulation (1992) 1.45
Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J (1998) 1.44
Atrial fibrillation begets trouble. Heart (1997) 1.43
Unrecognized dyslipoproteinemia in United Kingdom families recruited to a genetic register because of unexplained coronary heart disease. J Lab Clin Med (1994) 1.42
Do patients with neurally mediated syncope have augmented vagal tone? Am J Cardiol (1993) 1.41
Implantable cardioverter defibrillators and fitness to drive. Lancet (1994) 1.41
Effect of magnesium sulphate in patients with unstable angina. A double blind, randomized, placebo-controlled study. Eur Heart J (1997) 1.41
Influence of the infarct site on the identification of patients with ventricular tachycardia after myocardial infarction based on the time-domain and spectral turbulence analysis of the signal-averaged electrocardiogram. Clin Cardiol (1995) 1.41
The Percutaneous Cardiac Mapping and Ablation Registry: final summary of results. Pacing Clin Electrophysiol (1988) 1.39
Predictive value of wavelet decomposition of the signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy. Eur Heart J (2000) 1.39
Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems? J Cardiovasc Electrophysiol (1999) 1.39
Current concepts in atrial fibrillation. Br J Hosp Med (1993) 1.39
Influence of posture and reference point on central venous pressure measurement. BMJ (1991) 1.39
Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation (1992) 1.38
Successful radiofrequency ablation of accessory pathways with the first energy delivery: the anatomic and electrical characteristics. Eur Heart J (1996) 1.38
Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions. Postgrad Med J (1985) 1.38
Selection of dichotomy limits for multifactorial prediction of arrhythmic events and mortality in survivors of acute myocardial infarction. Eur Heart J (1997) 1.38
The NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices. Pacing Clin Electrophysiol (1987) 1.37
Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J (1984) 1.35
Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc Res (1988) 1.29
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 1.29
Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections. Circulation (1991) 1.27
Heart rate variability. Clin Cardiol (1990) 1.27
Adenosine in the diagnosis of broad complex tachycardia. Lancet (1988) 1.27
Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J (1982) 1.26
Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol (1995) 1.26
Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. Br Heart J (1991) 1.25
Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. Am J Cardiol (1983) 1.23
QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol (1994) 1.22
A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme. Br J Cancer (2012) 1.21
Evaluation of ocular health among alachlor manufacturing workers. J Occup Med (1994) 1.20
Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol (1996) 1.19
Increased monocyte tissue factor expression in coronary disease. Br Heart J (1995) 1.19
Signal-averaged electrocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.18
Celiac disease and immunoglobulin a deficiency: how effective are the serological methods of diagnosis? Clin Diagn Lab Immunol (2002) 1.18
Ventricular tachycardia associated with flecainide. Lancet (1982) 1.17
A case of a Dandy-Walker variant: the importance of a multidisciplinary team approach using complementary techniques to obtain accurate diagnostic information. Br J Radiol (2008) 1.17
Adenosine and cardiac arrhythmias. BMJ (1992) 1.15
Sinus node dysfunction associated with absence of right superior vena cava. Br Heart J (1979) 1.15
Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol (2000) 1.15
Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol (1997) 1.14
The use of active fixation electrodes for permanent endocardial pacing via a persistent left superior vena cava. Pacing Clin Electrophysiol (1982) 1.14
Mystery of QTc interval dispersion. Am J Cardiol (1997) 1.14
Identification and catheter ablation of extracardiac and intracardiac components of ligament of Marshall tissue for treatment of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (2001) 1.13
Electrophysiological effects of sotalol--just another beta blocker? Br Heart J (1982) 1.13
Diurnal variation of the QT interval--influence of the autonomic nervous system. Br Heart J (1986) 1.13
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. J Card Fail (1999) 1.13
Implantable automatic scanning pacemaker for termination of supraventricular tachycardia. Am J Cardiol (1982) 1.13
Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am J Cardiol (1989) 1.13